Trial Profile

An Open Label Study to Determine the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Subjects With Fatty Acid Oxidation Disorders (FAOD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavodelpar (Primary)
Indications Metabolic disorders
Focus Adverse reactions
Sponsors Reneo Pharmaceuticals

Most Recent Events

07 Dec 2022 Status changed from active, no longer recruiting to completed.
09 Aug 2022 According to a Reneo Pharmaceuticals media release, data from this trial will be presented at the International Network for Fatty Acid Oxidation Research and Management (INFORM) Conference, Aug 28-29 (Freiburg, Germany).
26 Jul 2022 Results published in Reneo Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com